Syncona Limited (SYNC), a leading life science investor, has announced that its portfolio company Resolution Therapeutics has published positive six-month interim data from the Phase I/II EMERALD trial evaluating RTX001, an investigational engineered macrophage cell therapy for end-stage liver disease. The data, presented at the American Association for the Study of Liver Diseases meeting in Denver, Colorado, showed a 42% relative risk reduction in death, liver transplant or hepatic decompensation versus an external control. The announcement represents what Syncona has designated a key value inflection point (KVIP) for the portfolio company, in which Syncona holds an 82.8% ownership stake valued at £89.0 million as of 30 June 2026.

Key Points

  • Syncona Limited (SYNC) is a life science investor with a maturing portfolio of clinical-stage companies
  • Portfolio company Resolution Therapeutics reported positive interim Phase I/II EMERALD trial data for RTX001 in end-stage liver disease
  • Six-month data showed a 42% relative risk reduction in death, liver transplant or hepatic decompensation; Syncona's holding in Resolution was valued at £89.0 million with an 82.8% ownership stake as of 30 June 2026
  • Investors should watch Resolution's pre-IND meeting with the FDA scheduled for December 2026, which will determine the pathway towards a planned pivotal trial

RTX001 Demonstrates 42% Relative Risk Reduction and Favourable Tolerability in EMERALD Phase I/II Trial

The six-month interim analysis compared nine RTX001-treated patients in the EMERALD study against 21 standard-of-care patients in OPAL, Resolution's natural history external control study. Two of nine RTX001-treated patients (22%) experienced death, liver transplant or a protocol-defined hepatic decompensation event within six months, compared with eight of 21 patients (38%) in OPAL. RTX001 was well tolerated, with no infusion-related serious adverse reactions and no severe treatment-related adverse events. Pharmacodynamic biomarker analyses demonstrated reduced inflammatory pathway activity and significant reductions in markers of fibrogenesis, consistent with the therapy's engineered mechanism of action.

Resolution Therapeutics Targets FDA Pre-IND Meeting in December 2026 Ahead of Planned Pivotal Study

Building on the interim results, Resolution Therapeutics has been granted a pre-investigational new drug (pre-IND) meeting with the US Food and Drug Administration in December 2026, a step the company intends to use to advance RTX001 into a pivotal trial. The EMERALD trial has completed enrolment with 15 patients dosed, and primary analysis is expected in 2028. RTX001 is an autologous therapy engineered with mRNA encoding IL-10 and MMP-9, designed to enhance anti-inflammatory and anti-fibrotic activity. Resolution is also extending its Regenerative Macrophage Therapy platform to lung fibrosis and an in vivo modality, broadening the potential pipeline beyond liver disease.

Syncona's £89.0 Million Stake in Resolution Reaches a Designated Key Value Inflection Point

Syncona has formally classified the publication of Resolution's interim clinical data as a key value inflection point, defined in the announcement as a material de-risking event for a portfolio company with the potential to drive significant net asset value growth and enable access to capital, including through financings and initial public offerings. Syncona held Resolution at a valuation of £89.0 million with an 82.8% ownership position as of 30 June 2026. The announcement states that KVIPs can underpin progression to subsequent value inflection events. As a life science investor reliant on portfolio company clinical success, Syncona's NAV trajectory remains closely tied to Resolution's ability to advance RTX001 through late-stage development.

End-Stage Liver Disease Affects Over 500,000 US Patients With No Approved Disease-Modifying Therapy

The announcement highlights a substantial unmet medical need underpinning Resolution's commercial opportunity. More than 500,000 people in the US currently live with end-stage liver disease, a figure the company states is expected to grow to 600,000 by 2040. Median survival falls to approximately two years following a first hepatic decompensation event and to nine months after a second. The condition causes more than 50,000 deaths in the US annually, and no approved disease-modifying therapy currently exists. Liver transplantation remains the only curative option, yet most patients who require one do not receive one, leaving RTX001 targeting a disease area with extremely limited alternatives.